| Trial ID: | L6326 |
| Source ID: | NCT02220907
|
| Associated Drug: |
Teneligliptin/Canagliflozin
|
| Title: |
Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02220907/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Teneligliptin/Canagliflozin
|
| Outcome Measures: |
Primary: Number of Participants With Adverse Events, 52 Weeks | Secondary: Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c), The change from baseline in percentage of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 52., Baseline, 52 Weeks|Change From Baseline in Fasting Plasma Glucose Level, The change from baseline in fasting plasma glucose level collected at Week 52., Baseline, 52 Weeks|Percentage Change in Body Weight From Baseline, The percentage change from baseline in body weight collected at Week 52., Baseline, 52 Weeks
|
| Sponsor/Collaborators: |
Sponsor: Mitsubishi Tanabe Pharma Corporation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
153
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-08
|
| Completion Date: |
2016-02
|
| Results First Posted: |
2018-08-16
|
| Last Update Posted: |
2018-11-01
|
| Locations: |
Research site, Chubu, Japan|Research site, Chugoku, Japan|Research site, Hokkaido, Japan|Research site, Kanto, Japan|Research site, Kyushu, Japan|Research site, Tohoku, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT02220907
|
